Cardosal Plus 20mg/12.5mg 28 tablets — Made in Germany — Free Delivery

Product description

Tablets "Cardosal® plus 20 / 12.5" are used for the treatment of essential hypertension. The combined preparation is intended for adult patients in whom the use of olmesartan medoxomil alone does not provide a decrease in blood pressure to the required level.

Compound

One film-coated tablet contains (active ingredients):

olmesartan medoxomil - 20 mg;

hydrochlorothiazide - 12.5 mg.

Excipients: microcrystalline cellulose, low-substituted hydroxypropyl cellulose, lactose monohydrate, hydroxypropyl cellulose, magnesium stearate; shell: Opadry O2A22352 or O2A24576 (hypromellose, talc, titanium dioxide (E 171), iron oxide yellow (E172), iron oxide red (E 172)).

Contraindications

• an allergic reaction (hypersensitivity) to active substances, to any of the excipients or to other sulfonamide derivatives (hydrochlorothiazide is also a sulfonamide derivative);
• severe renal dysfunction (creatinine clearance <30 ml / minute);
• persistent hypokalemia, hypercalcemia, hyponatremia, and clinically significant hyperuricemia;
• severe liver dysfunction, cholestasis and obstructive diseases of the biliary tract;
• pregnancy or planning a pregnancy;
• the combined use of the preparation "Cardosal® plus 20 / 12.5" and preparations containing aliskiren is contraindicated in patients with diabetes mellitus or impaired renal function (GFR <60 ml / minute / 1.73 m2).

Mode of application

Cardosal® plus 20 / 12.5 is not the first choice. It is intended for patients in whom the use of olmesartan medoxomil alone at a dose of 20 mg does not provide the required level of blood pressure.

The tablets of the preparation are taken 1 time per day, regardless of the meal.

In the presence of clinical indications, it is allowed to transfer the patient from monotherapy with olmesartan medoxomil at a dose of 20 mg immediately to the combined preparation, however, it should be borne in mind that the maximum hypotensive effect of olmesartan medoxomil is achieved 8 weeks after the start of treatment.

Dose titration of each of the components is recommended.

Olmesartan medoxomil / hydrochlorothiazide at a dose of 20 / 12.5 mg can be prescribed to patients in whom the use of olmesartan medoxomil at a dose of 20 mg alone does not achieve the required blood pressure level.

The tablets are swallowed whole with a sufficient amount of liquid (for example, a glass of water). The tablets should not be chewed. It is recommended to take the preparation at the same time every day.

Application features

Pregnant

This preparation is contraindicated in pregnant women or women planning a pregnancy.

It is not recommended to use the preparation "Cardosal® plus 20 / 12.5" during breastfeeding. When using this preparation while breastfeeding, the dose should be as low as possible.

Children

The safety and efficacy of this preparation in children (under the age of 18) have not been established. No data available.

Drivers

The preparation can cause a slight or moderate effect on the ability to drive vehicles and work with other mechanisms. Sometimes patients taking antihypertensive preparations may experience dizziness and fatigue, as a result of which the response may decrease.

Overdose

There is no specific information regarding the symptoms or treatment of an overdose with this preparation.

The patient should be closely monitored and symptomatic supportive care given. Treatment is symptomatic and depends on the time elapsed since the preparation was taken and on the severity of the symptoms.

Side effects

Most often, when using the preparation, such adverse reactions occur as headache (2.9%), dizziness (1.9%), fatigue (1.0%).

Storage conditions

No special storage conditions are required. Keep out of the reach of children.

The shelf life is 5 years.